Mirati Therapeutics, Inc. (NASDAQ:MRTX) rose 3.4% during trading on Monday after HC Wainwright raised their price target on the stock to $40.00. HC Wainwright currently has a buy rating on the stock. Mirati Therapeutics traded as high as $35.00 and last traded at $35.79. Approximately 692,892 shares were traded during mid-day trading, an increase of 53% from the average daily volume of 452,178 shares. The stock had previously closed at $34.60.
Several other brokerages also recently commented on MRTX. SunTrust Banks boosted their target price on shares of Mirati Therapeutics to $40.00 and gave the company a “buy” rating in a research note on Friday, March 9th. Cowen started coverage on shares of Mirati Therapeutics in a research report on Thursday, December 21st. They set an “outperform” rating on the stock. BidaskClub upgraded shares of Mirati Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. Cann reiterated a “buy” rating and set a $18.00 price target on shares of Mirati Therapeutics in a research report on Monday, January 8th. Finally, Leerink Swann upgraded shares of Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $9.00 price target on the stock in a research report on Tuesday, November 14th. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Mirati Therapeutics has a consensus rating of “Buy” and an average price target of $25.44.
In other Mirati Therapeutics news, SVP Jamie Christensen sold 14,725 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $22.99, for a total transaction of $338,527.75. Following the completion of the sale, the senior vice president now directly owns 6,395 shares of the company’s stock, valued at approximately $147,021.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Jamie A. Donadio sold 51,875 shares of the business’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $27.13, for a total value of $1,407,368.75. Following the sale, the chief financial officer now directly owns 9,375 shares of the company’s stock, valued at $254,343.75. The disclosure for this sale can be found here. In the last quarter, insiders have sold 125,014 shares of company stock worth $3,477,750. 5.10% of the stock is owned by corporate insiders.
The firm has a market cap of $1,010.00, a price-to-earnings ratio of -12.19 and a beta of 2.00.
Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by ($0.06). equities analysts expect that Mirati Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://weekherald.com/2018/03/14/mirati-therapeutics-mrtx-stock-price-up-3-4-following-analyst-upgrade.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.